Implementation of latent tuberculosis infection screening and novel treatment one-month Rifapentine plus Isoniazid in end-stage renal disease patients and on renal replacement therapy

This is a collaborate study done with the Renal Division, Department of Medicine, Faculty of Medicine, Chulalongkorn University. This study is a single-center, prospective cohort study conducted at the Faculty of Medicine, Chulalongkorn University. 60-90 ESRD patients and on renal replacement therapy will be enrolled into this study. This study will assess the following: the study pharmacokinetic parameters of Rifapentine in ESRD patients and on renal replacement therapy; study safety and tolerability of one-month Rifapentine plus Isoniazid regimen in ESRD patients receiving renal replacement therapy; study adherence rates; study treatment discontinuation rate from adverse events; the prevalence of LTBI in patients preparing for kidney transplantation; factors associated with LTBI in ESRD patients and on renal replacement therapy; TB incidences among participants receiving the regimen; TB incidences among participants after transplantation; investigate patterns of antibiotic resistance of Mycobacterium tuberculosis in failed participants, and all-cause mortality rates among participants during the 3-year follow up period and after transplantation.